Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy

January 12, 2024 Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera

Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
News
national-cancer-institute-l8twzt4ccvq-unsplash_1

Eli Lilly launches digital healthcare process

January 5, 2024 Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …
News

Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement

January 5, 2024 Medical Communications LG Chem Life Sciences, License Agreement, Pharmacy, Rhythm Pharmaceuticals, clinical trial

Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a global licensing agreement for LB54640, …
News

Renovos Biologics gains FDA Breakthrough Device Designation for Renovite

January 4, 2024 Medical Communications FDA, Musculo-skeletal disorder, Renovos Biologics, breakthrough device designation

Renovos Biologics has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead …
News

Calliditas Therapeutics gains FDA approval of Tarpeyo

December 22, 2023 Medical Communications Calliditas, FDA, Nephrology, kidneys

Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to …
News

FDA approves AstraZeneca and Ionis’s Wainua

December 22, 2023 Medical Communications AstraZeneca, FDA, Ionis, Neurology, Wainua

AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment …
News

FDA approves Glaukos’ iDose TR treatment for glaucoma disease

December 15, 2023 Medical Communications FDA, Glaukos, Opthalmology, iDose TR, ocular hypertension, open-angle glaucoma

Glaukos Corporation has announced that the US Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for …
News

FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment

December 14, 2023 Medical Communications FDA, Mission Therapeutics, Nephrology, acute kidney injury, clinical trial

Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application …
News

FDA grants Kyverna Therapeutics fast track designation for myasthenia gravis treatment

December 14, 2023 Medical Communications FDA, Kyverna Therapeutics, Musculo-skeletal disorder, myasthenia gravis

Kyverna Therapeutics has announced that it has gained fast track designation from the US Food and Drug Administration (FDA) for …
News

Merck and Moderna initiate phase 3 study of NSCLC treatment

December 13, 2023 Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial

Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …
News
milad-fakurian-58z17lnvs4u-unsplash_2

PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research

December 13, 2023 Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM

PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on …
News

EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

December 12, 2023 Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma

Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …
News

GSK’s Jemperli approved in EU as treatment for endometrial cancer

December 11, 2023 Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …
News

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023 Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …
News

Regeneron shares data for multiple myeloma treatment

December 8, 2023 Medical Communications Cancer, Oncology, Regeneron, clinical trial

Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026